COVID-19 May Awaken Dormant Viruses and One Is Linked to Long COVID

No single marker automatically proves that a virus is causing symptoms.

This is especially important in long COVID research because people can have very different biological profiles despite sharing the same broad diagnosis.

Long COVID may not be one disease

One of the most important insights emerging from post-COVID research is that long COVID may represent a collection of biological pathways rather than one uniform disease mechanism.

Different patients can experience very different combinations of symptoms, including fatigue, post-exertional worsening, cognitive difficulties, sleep problems, changes in smell or taste, shortness of breath, palpitations and neurological symptoms.

Several mechanisms have been proposed or investigated, including persistent immune activation, autonomic dysfunction, vascular abnormalities, tissue injury, altered metabolism, gastrointestinal changes and viral persistence.

Viral reactivation may fit into this picture as one possible pathway.

That would explain why two people who both develop long COVID might not have identical biological abnormalities.

A useful comparison: long COVID and other post-viral illnesses

Post-viral symptoms are not unique to COVID-19. Medicine has long recognised that some infections can be followed by prolonged fatigue, neurological complaints or other persistent symptoms.

What makes long COVID particularly important scientifically is its scale and the opportunity to study these processes using modern immunology, genomics and large patient cohorts.

The comparison also provides a useful caution.

If researchers discover that viral reactivation occurs in some people after COVID-19, that would not necessarily mean SARS-CoV-2 is uniquely responsible. Instead, it could reveal a broader biological pattern in which severe or disruptive infections temporarily alter immune control over latent viruses.

Could viral reactivation explain long COVID?

It may help explain some aspects of some cases, but current evidence does not justify saying that viral reactivation is the universal cause of long COVID.

There are several possibilities.

First, SARS-CoV-2 could trigger immune changes that allow a latent virus to reactivate. That reactivation could then contribute to inflammation or symptoms.

Second, the same immune dysfunction could independently cause long COVID symptoms while also allowing latent viruses to become more active. In this scenario, viral reactivation would be a marker of the underlying problem rather than its primary cause.

Third, different patients could experience different combinations of these mechanisms.

This third possibility may ultimately prove especially important for treatment research.

Why one blood test is unlikely to solve the mystery

It can be tempting to imagine a future test that simply checks for a reactivated virus and diagnoses long COVID.

Real biology is unlikely to be that straightforward.

Because many latent viruses are common in the population, detecting evidence of previous infection is not enough. Scientists need to determine whether the virus is unusually active, whether that activity correlates with specific symptoms and whether treating the viral activity improves those symptoms.

The final step is crucial.

If a treatment reduces evidence of EBV reactivation but patients do not improve, the virus may be an innocent bystander or merely one component of a much larger process.

Conversely, if targeted treatment consistently improves a carefully defined subgroup of patients with evidence of reactivation, that would provide much stronger evidence for a causal role.

The therapeutic implications could be significant

If viral reactivation contributes meaningfully to a subgroup of long COVID patients, it could eventually help scientists develop more targeted treatment strategies.

Instead of treating every patient with the same approach, clinicians could potentially identify biological subgroups based on immune signatures, viral activity or other measurable features.

This is the broader promise of precision medicine.

However, antiviral drugs should not be assumed to be appropriate simply because a latent virus is detected. Antiviral treatment can have side effects, and evidence that a virus is present does not automatically demonstrate that suppressing it will improve symptoms.

Clinical trials are therefore essential before such approaches become routine treatment.

What researchers still need to prove

The next stage of research needs to move beyond snapshots of patients and establish clearer cause-and-effect relationships.

• Does SARS-CoV-2 consistently increase reactivation of particular latent viruses?
• Which patients are most likely to experience viral reactivation?
• Does the timing of reactivation match the emergence of long COVID symptoms?
• Are specific viral signatures associated with particular symptom clusters?
• Does suppressing the reactivated virus improve patient outcomes?
• How do viral reactivation, inflammation and immune dysfunction interact?

Answering these questions will require studies that follow people from acute infection through recovery and, when necessary, into the period of persistent illness.

A new way to think about the body’s viral ecosystem

The most interesting implication of this research may extend beyond COVID-19.

For decades, infectious disease research often focused on individual pathogens: identify the virus, identify the disease and develop a treatment.

The emerging science of the human virome suggests a more complicated picture.

The body can carry viral genetic material and latent viruses for years without obvious illness. The immune system continually negotiates with these biological passengers.

An infection such as COVID-19 could potentially disrupt that equilibrium.

This does not mean the body is permanently “full of dangerous viruses.” Rather, it means that infection, immunity and the microbiological environment inside humans may be more interconnected than previously appreciated.

What this means for people with long COVID

For patients experiencing persistent symptoms after COVID-19, the research offers a potentially useful scientific direction, but it should not encourage self-diagnosis.

Long COVID is a clinical condition with multiple possible mechanisms. A positive antibody test for a common virus does not establish that the virus is causing ongoing symptoms.

People with persistent or worsening symptoms should discuss them with a qualified healthcare professional, particularly when symptoms interfere substantially with daily activities or involve potentially serious signs such as chest pain, severe breathing difficulty, fainting or new neurological deficits.

The practical message is therefore cautious but hopeful: researchers are discovering increasingly detailed biological clues, but the science has not yet reduced long COVID to a single virus or single treatment.

The bigger picture: COVID-19 may have exposed a hidden layer of infection biology

The most valuable lesson from the research into dormant viruses is not that COVID-19 has “awakened hidden viruses” in everyone.

It is that an acute infection can potentially alter a complex biological ecosystem that includes the immune system, latent viruses and the body’s tissues.

That possibility could change how scientists investigate post-infectious disease.

Instead of asking only, “Is SARS-CoV-2 still present?”, researchers may increasingly ask, “What changed in the body’s biological environment after SARS-CoV-2 infection?”

That is a much broader question — and potentially a more useful one.

Conclusion: A clue, not yet a complete explanation

Research suggesting that COVID-19 can be associated with the reactivation of dormant viruses offers an intriguing clue in the long COVID puzzle. Herpesviruses, particularly EBV, have attracted considerable attention because they can remain latent in the body and become active when immune control changes.

But the evidence should not be overstated. Viral reactivation is not established as the single cause of long COVID. For some people, it may be part of a chain of biological events; for others, it may simply reflect immune disruption occurring alongside persistent symptoms.

The most promising direction is therefore not a search for one “hidden virus” responsible for every case. It is the development of better biological profiles that can reveal why different patients develop different forms of post-COVID illness.

If researchers can determine when viral reactivation is a driver rather than a bystander, the discovery could eventually lead to more precise diagnosis and treatment. Until then, the science offers an important reminder: after an infection appears to have ended, the immune system’s relationship with the body’s resident viruses may still be telling a much bigger story.</p